Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Tomoyuki Satake

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9445-7738; OpenAlex author ID A5020568554. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2022: 2 papers · 2023: 4 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer. First author DOI 10.1093/jjco/hyag044↗
  2. Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles. Co-author DOI 10.3389/fonc.2025.1682072↗
  3. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Co-author DOI 10.1002/cam4.70474↗
  4. Covered self-expandable metallic stent placement for tumor bleeding from duodenal invasion in patients with unresectable pancreatic cancer. Co-author DOI 10.1002/deo2.361↗
  5. A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study. Co-author DOI 10.1016/j.eclinm.2024.102936↗
  6. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites. Co-author DOI 10.1016/j.pan.2024.03.015↗
  7. Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. Co-author DOI 10.1007/s00535-022-01944-x↗
  8. Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1186/s13014-023-02367-5↗
  9. Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1186/s13014-023-02377-3↗
  10. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3048794/v1↗
  11. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. Co-author DOI 10.1007/s00535-022-01920-5↗
  12. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10147-022-02186-w↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuichi Mitsunaga · 6 shared papers, 2023–2026 · strength 1.18
  2. Mitsuhito Sasaki · 6 shared papers, 2023–2026 · strength 1.18
  3. Masafumi Ikeda · 6 shared papers, 2023–2026 · strength 1.18
  4. Hiroshi Imaoka · 6 shared papers, 2023–2026 · strength 1.18
  5. Taro Shibuki · 5 shared papers, 2023–2026 · strength 1.00
  6. Tomonao Taira · 5 shared papers, 2023–2026 · strength 1.00
  7. Kanae Inoue · 5 shared papers, 2023–2026 · strength 1.00
  8. Takuji Okusaka · 5 shared papers, 2022–2024 · strength 0.95
  9. Chigusa Morizane · 4 shared papers, 2022–2024 · strength 0.76
  10. Akihiro Ohba · 2 shared papers, 2022–2023 · strength 0.34
  11. Tomoya Kawase · 2 shared papers, 2024–2025 · strength 0.34
  12. Shogo Baba · 2 shared papers, 2024–2025 · strength 0.34
  13. Johji Imura · 2 shared papers, 2024–2025 · strength 0.34
  14. Hiroshi Kurahara · 2 shared papers, 2024–2025 · strength 0.34
  15. Hideyuki Oi · 2 shared papers, 2024–2025 · strength 0.34
  16. Hiroshi Nishihara · 2 shared papers, 2024–2025 · strength 0.34
  17. Koji Yoshida · 2 shared papers, 2024–2025 · strength 0.34
  18. Masataka Amisaki · 1 shared paper, 2026 · strength 0.28
  19. Akira Kawai · 1 shared paper, 2023 · strength 0.22
  20. Mariko Nishioka · 1 shared paper, 2024 · strength 0.20
  21. Koh Fukushi · 1 shared paper, 2024 · strength 0.20
  22. Satoshi Nara · 1 shared paper, 2024 · strength 0.20
  23. Nobuyoshi Hiraoka · 1 shared paper, 2024 · strength 0.20
  24. Minoru Esaki · 1 shared paper, 2024 · strength 0.20
  25. Akira Kawai · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.